Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient

Sha-Sha Wang,Fang Wang,Zhen Zeng,Fang Gao,Huan-Huan Liu,Hui-Na Wang,Yi Hu,Hai-Feng Qin

DOI: https://doi.org/10.3389/fonc.2022.1113289

IF: 4.7

2022-12-13

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.929763.].

oncology

What problem does this paper attempt to address?

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Min Yuan,Zhongzheng Zhu,Wei Mao,Hui Wang,Hong Qian,Jianguo Wu,Xianling Guo,Qing Xu

DOI: https://doi.org/10.3389/fonc.2021.796625

IF: 4.7

2022-01-04

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.683502.].

oncology
Corrigendum: Case report: Long remission and survival following immunotherapy in a case of pulmonary pleomorphic carcinoma

Tongshan Wang,Muyang Chen,Anpeng Wang,Hao Zhang

DOI: https://doi.org/10.3389/fimmu.2024.1530843

IF: 7.3

2024-12-03

Frontiers in Immunology

Abstract:This article is a correction to: Case Report: Long Remission and Survival Following Immunotherapy in a Case of Pulmonary Pleomorphic Carcinoma

immunology
Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer

Gianluca Mauri,Giorgio Patelli,Viviana Gori,Calogero Lauricella,Benedetta Mussolin,Alessio Amatu,Katia Bencardino,Federica Tosi,Erica Bonazzina,Emanuela Bonoldi,Alberto Bardelli,Salvatore Siena,Andrea Sartore-Bianchi

DOI: https://doi.org/10.3389/fonc.2023.1147497

IF: 4.7

2023-03-28

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.1030232.].

oncology
Corrigendum: Combined Scutellarin and C18H17NO6 Imperils the Survival of Glioma: Partly Associated With the Repression of PSEN1/PI3K-AKT Signaling Axis

Xiu-Ying He,Yang Xu,Qing-Jie Xia,Xiao-Ming Zhao,Shan Li,Xiao-Qiong He,Ru-Rong Wang,Ting-Hua Wang

DOI: https://doi.org/10.3389/fonc.2022.872110

IF: 4.7

2022-03-07

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.663262.].

oncology
Corrigendum: Regulation of microrna-497-targeting AKT2 influences tumor growth and chemoresistance to cisplatin in lung cancer

Lin Wang,Xiang-Bo Ji,Li-Hong Wang,Jian-Ge Qiu,Feng-Mei Zhou,Wen-Jing Liu,Di-di Wan,Marie Chai-mi Lin,Ling-Zhi Liu,Jian-Ying Zhang,Bing-Hua Jiang

DOI: https://doi.org/10.3389/fcell.2022.1008088

IF: 5.5

2022-09-23

Frontiers in Cell and Developmental Biology

Abstract:[This corrects the article DOI: 10.3389/fcell.2020.00840.].

cell biology,developmental biology
Corrigendum: Neoadjuvant Tislelizumab Combined with Chemotherapy in Locally Advanced Oral or Oropharyngeal Squamous Cell Carcinoma: a Real-World Retrospective Study.

Wen-Jie Wu,Qian Liu,Pu-Gen An,Lin Wang,Jian-Yun Zhang,Yan Chen,Tong Zhang,Jie Zhang

DOI: https://doi.org/10.3389/fimmu.2023.1346845

IF: 7.3

2024-01-01

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1282629.].
Corrigendum to "A Novel Inhibitor of MDM2 Oncogene Blocks Metastasis of Hepatocellular Carcinoma and Overcomes Chemoresistance" [genes Dis 694 (2019) 419-430].

Wei Wang,Bo Hu,Jiang-Jiang Qin,Jianwen Cheng,Xin Li,Mehrdad Rajaei,Jia Fan,Xin-Rong Yang,Ruiwen Zhang

DOI: https://doi.org/10.1016/j.gendis.2019.12.006

IF: 7.376

2019-01-01

Genes & Diseases

Abstract:[This corrects the article DOI: 10.1016/j.gendis.2019.06.001.].
Corrigendum: The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma

Fangling Cheng,Po Zhang,Qungen Xiao,Youwei Li,Minhai Dong,Heping Wang,Dong Kuang,Yue He,Qiuhong Duan,Feng Mao,Baofeng Wang,Dongsheng Guo

DOI: https://doi.org/10.3389/fonc.2020.591112

2020-09-25

Abstract:[This corrects the article DOI: 10.3389/fonc.2019.00447.].
Corrigendum to “ARMCX Family Gene Expression Analysis and Potential Prognostic Biomarkers for Prediction of Clinical Outcome in Patients with Gastric Carcinoma”

TingAn Wang,HuaGe Zhong,YuZhou Qin,WeiYuan Wei,Zhao Li,MingWei Huang,XiaoLing Luo

DOI: https://doi.org/10.1155/2021/3179693

2021-02-09

BioMed Research International

Abstract:[This corrects the article DOI: 10.1155/2020/3575038.].

biotechnology & applied microbiology,medicine, research & experimental
Corrigendum: Comprehensive transcriptomic analysis of critical RNA regulation associated with metabolism and prognosis in clear cell renal carcinoma

Si Liu,Honglan Zhou,Gang Wang,Xin Lian

DOI: https://doi.org/10.3389/fcell.2023.1216783

IF: 5.5

2023-06-01

Frontiers in Cell and Developmental Biology

Abstract:[This corrects the article DOI: 10.3389/fcell.2021.709490.].

cell biology,developmental biology
Corrigendum: LCN2 Is a Potential Biomarker for Radioresistance and Recurrence in Nasopharyngeal Carcinoma

Meng-Xia Zhang,Li Wang,Lei Zeng,Zi-Wei Tu

DOI: https://doi.org/10.3389/fonc.2021.670714

IF: 4.7

2021-03-18

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2020.605777.].

oncology
Corrigendum: EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy As First-Line Therapy for Non-Small Cell Lung Cancer Patients with the L858R Point Mutation.

Jianlin Xu,Haitang Yang,Bo Jin,Yuqing Lou,Yanwei Zhang,Xueyan Zhang,Hua Zhong,Huiming Wang,Dan Wu,Baohui Han

DOI: https://doi.org/10.1038/srep38270

IF: 4.6

2016-01-01

Scientific Reports

Abstract:Scientific Reports 6: Article number: 36371; published online: 04 November 2016; updated: 01 December 2016
Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Qiuqiang Chen,Gang Jia,Xilin Zhang,Wenxue Ma

DOI: https://doi.org/10.3389/fimmu.2024.1376045

IF: 7.3

2024-01-31

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1332057.].

immunology
Corrigendum: Molecular Portrait of GIST Associated With Clinicopathological Features: A Retrospective Study With Molecular Analysis by a Custom 9-Gene Targeted Next-Generation Sequencing Panel

Haoran Qian,Na Yan,Xiaotong Hu,Junchang Jiang,Zhengzheng Cao,Dan Shen

DOI: https://doi.org/10.3389/fgene.2022.945357

IF: 3.7

2022-06-28

Frontiers in Genetics

Abstract:[This corrects the article DOI: 10.3389/fgene.2022.864499.].

genetics & heredity
Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

Yunfu Deng,Guangzhi Ma,Karin A. Vallega,Dongsheng Wang,Mingliang Wang,Changwei Wang,Shaomeng Wang,Suresh S. Ramalingam,Shi-Yong Sun

DOI: https://doi.org/10.1038/s41417-022-00479-w

IF: 5.854

2022-05-10

Cancer Gene Therapy

Abstract:Cancer Gene Therapy, Published online: 10 May 2022; doi:10.1038/s41417-022-00479-w Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

oncology,genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology
Corrigendum to “Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells”

Haibo Xing,Mengting Tong,Jing Wang,Hanqing Hu,Chongya Zhai,Chunhui Huang,Da Li

DOI: https://doi.org/10.1155/2022/9767389

2022-01-01

BioMed Research International

Abstract:[This corrects the article DOI: 10.1155/2018/3195025.].
Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis

Qitong Chen,Dengjie Ouyang,Munawar Anwar,Ning Xie,Shouman Wang,Peizhi Fan,Liyuan Qian,Gannong Chen,Enxiang Zhou,Lei Guo,Xiaowen Gu,Boni Ding,Xiaohong Yang,Liping Liu,Chao Deng,Zhi Xiao,Jing Li,Yunqi Wang,Shan Zeng,Jinhui Hu,Wei Zhou,Bo Qiu,Zhongming Wang,Jie Weng,Mingwen Liu,Yi Li,Tiegang Tang,Jianguo Wang,Hui Zhang,Bin Dai,Wuping Tang,Tao Wu,Maoliang Xiao,Xiantao Li,Hailong Liu,Lai Li,Wenjun Yi,Quchang Ouyang

DOI: https://doi.org/10.3389/fonc.2021.661128

IF: 4.7

2021-03-05

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2020.00811.].

oncology
[Corrigendum] Role of 4‑aminobutyrate Aminotransferase (ABAT) and the Lncrna Co‑expression Network in the Development of Myelodysplastic Syndrome

Yanzhen Chen,Guangjie Zhao,Nianyi Li,Hongguang Luo,Xiaoqin Wang,Jingwen Gu

DOI: https://doi.org/10.3892/or.2022.8447

2022-01-01

Oncology Reports

Abstract:Subsequently to the publication of the above article, and a Corrigendum that has already been published with the intention of showing corrected versions of Figs. 1 and 8 (DOI: 10.3892/or.2022.8348; published online on June 14, 2022), the authors have belatedly realized that the revisions made to Fig. 8 necessitated changes that should have been introduced into Fig. 9, although these were not attended to in the first corrigendum. Essentially, Fig. 8 was revised as the cell apoptosis and cell proliferation assays therein were poorly presented, which made the interpretation of the data difficult; Fig. 9 showed the fractions of apoptotic cells in the SKM‑1 and THP‑1 cell lines with lncENST00000444102 overexpression as this pertained to Fig. 8. A revised version of Fig. 9, presenting the analysis of the data shown in the revised version of Fig. 8, is shown opposite. In addition to the revision of Fig. 9, the sentence starting on p. 517, left‑hand column, line 12 [“The flow cytometric apoptosis assay revealed that lncENST00000444102 overexpression promoted tumor cells to undergo apoptosis compared to control cells (P<0.001, Fig. 9)”] should be replaced with the following text, to reflect the change in the level of statistical significance: ‘The flow cytometric apoptosis assay revealed that lncENST00000444102 overexpression promoted tumor cells to undergo apoptosis compared to control cells (P<0.01, Fig. 9)”. Note that the revisions made to Figs. 8 and 9 in this paper have not had a major impact on the reported results, and do not affect the overall conclusions reported in the study. All the authors agree to the publication of this corrigendum. The authors are grateful to the Editor of Oncology Reports for allowing them the opportunity to publish this additional Corrigendum; furthermore, they apologize for any inconvenience caused to the readership of the Journal. [Oncology Reports 42: 509‑520, 2019; DOI: 10.3892/or.2019.7175]
Correction to: Recurrent fibroblast growth factor receptor3 fusion glioblastoma treated with pemigatinib: A case report and review of the literature

DOI: https://doi.org/10.1093/noajnl/vdae116

2024-07-08

Abstract:[This corrects the article DOI: 10.1093/noajnl/vdae072.].
Corrigendum: Transmembrane and coiled-coil domains 3 is a diagnostic biomarker for predicting immune checkpoint blockade efficacy in hepatocellular carcinoma

Xinyao Hu,Hua Zhu,Shi Feng,Chaoqun Wang,Yingze Ye,Xiaoxing Xiong

DOI: https://doi.org/10.3389/fgene.2022.1117731

IF: 3.7

2023-01-16

Frontiers in Genetics

Abstract:[This corrects the article DOI: 10.3389/fgene.2022.1006357.].

genetics & heredity

Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Corrigendum: Case report: Long remission and survival following immunotherapy in a case of pulmonary pleomorphic carcinoma

Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer

Corrigendum: Combined Scutellarin and C18H17NO6 Imperils the Survival of Glioma: Partly Associated With the Repression of PSEN1/PI3K-AKT Signaling Axis

Corrigendum: Regulation of microrna-497-targeting AKT2 influences tumor growth and chemoresistance to cisplatin in lung cancer

Corrigendum: Neoadjuvant Tislelizumab Combined with Chemotherapy in Locally Advanced Oral or Oropharyngeal Squamous Cell Carcinoma: a Real-World Retrospective Study.

Corrigendum to "A Novel Inhibitor of MDM2 Oncogene Blocks Metastasis of Hepatocellular Carcinoma and Overcomes Chemoresistance" [genes Dis 694 (2019) 419-430].

Corrigendum: The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma

Corrigendum to “ARMCX Family Gene Expression Analysis and Potential Prognostic Biomarkers for Prediction of Clinical Outcome in Patients with Gastric Carcinoma”

Corrigendum: Comprehensive transcriptomic analysis of critical RNA regulation associated with metabolism and prognosis in clear cell renal carcinoma

Corrigendum: LCN2 Is a Potential Biomarker for Radioresistance and Recurrence in Nasopharyngeal Carcinoma

Corrigendum: EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy As First-Line Therapy for Non-Small Cell Lung Cancer Patients with the L858R Point Mutation.

Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Corrigendum: Molecular Portrait of GIST Associated With Clinicopathological Features: A Retrospective Study With Molecular Analysis by a Custom 9-Gene Targeted Next-Generation Sequencing Panel

Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

Corrigendum to “Suppression of IL-6 Gene by shRNA Augments Gemcitabine Chemosensitization in Pancreatic Adenocarcinoma Cells”

Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis

[Corrigendum] Role of 4‑aminobutyrate Aminotransferase (ABAT) and the Lncrna Co‑expression Network in the Development of Myelodysplastic Syndrome

Correction to: Recurrent fibroblast growth factor receptor3 fusion glioblastoma treated with pemigatinib: A case report and review of the literature

Corrigendum: Transmembrane and coiled-coil domains 3 is a diagnostic biomarker for predicting immune checkpoint blockade efficacy in hepatocellular carcinoma